These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33437513)

  • 21. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
    Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M;
    Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy.
    Kulda V; Svaton M; Mukensnabl P; Hrda K; Dvorak P; Houdek Z; Houfkova K; Vrzakova R; Babuska V; Pesek M; Pesta M
    Oncol Lett; 2018 Jan; 15(1):592-599. PubMed ID: 29387235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.
    Nakata K; Ohuchida K; Mizumoto K; Kayashima T; Ikenaga N; Sakai H; Lin C; Fujita H; Otsuka T; Aishima S; Nagai E; Oda Y; Tanaka M
    Surgery; 2011 Nov; 150(5):916-22. PubMed ID: 22018284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion.
    Yu J; Ohuchida K; Mizumoto K; Fujita H; Nakata K; Tanaka M
    Cancer Biol Ther; 2010 Oct; 10(8):748-57. PubMed ID: 20703102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.
    de Jesus VHF; Camandaroba MPG; Calsavara VF; Riechelmann RP
    Ther Adv Med Oncol; 2020; 12():1758835920905408. PubMed ID: 32165927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of circulating MiR-30b-5p identifies advanced breast cancer.
    Estevão-Pereira H; Lobo J; Salta S; Amorim M; Lopes P; Cantante M; Reis B; Antunes L; Castro F; Palma de Sousa S; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
    J Transl Med; 2019 Dec; 17(1):435. PubMed ID: 31888645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.
    de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
    J Gastrointest Oncol; 2018 Oct; 9(5):806-819. PubMed ID: 30505579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
    Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
    Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.
    Huang H; Li X; Zhang X; Li Z; Han D; Gao W; Liu L; Peng C; Zhu H; Yu X
    Acta Biochim Biophys Sin (Shanghai); 2022 Dec; 54(12):1775-1788. PubMed ID: 36789695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs.
    Lee KH; Lee JK; Choi DW; Do IG; Sohn I; Jang KT; Jung SH; Heo JS; Choi SH; Lee KT
    Pancreas; 2015 Jul; 44(5):764-8. PubMed ID: 25906450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.
    Parasramka MA; Ali S; Banerjee S; Deryavoush T; Sarkar FH; Gupta S
    Mol Nutr Food Res; 2013 Feb; 57(2):235-48. PubMed ID: 23293055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-136-5p regulates gemcitabine resistance in pancreatic cancer via down-regulating ZNF32.
    Xu Y; Qin Y; Cui JX; Xu J
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10472-10482. PubMed ID: 33155203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
    Wu Y; Xu W; Yang Y; Zhang Z
    Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III.
    Visani M; de Biase D; Marucci G; Cerasoli S; Nigrisoli E; Bacchi Reggiani ML; Albani F; Baruzzi A; Pession A;
    Mol Oncol; 2014 Mar; 8(2):417-30. PubMed ID: 24412053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.
    Sahin TK; Isik A; Guven DC; Ceylan F; Babaoglu B; Akyol A; Yalcin S; Dizdar O
    Pancreatology; 2024 Mar; 24(2):279-288. PubMed ID: 38272717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer.
    Kang E; Jung SC; Nam SK; Park Y; Seo SH; Park KU; Oh HK; Kim DW; Kang SB; Lee HS
    Sci Rep; 2022 Feb; 12(1):2295. PubMed ID: 35145164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
    Inamoto T; Uehara H; Akao Y; Ibuki N; Komura K; Takahara K; Takai T; Uchimoto T; Saito K; Tanda N; Yoshikawa Y; Minami K; Hirano H; Nomi H; Kato R; Hayashi T; Azuma H
    Dis Markers; 2018; 2018():5468672. PubMed ID: 30026881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.